Analyse The Oncology Institute, Inc. (STLN) — Kairos Score 62/100

À propos de The Oncology Institute, Inc.

Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.

Informations clés

🕴️ Activité des initiés (90 jours)

2 transactions — 1 achats et 1 ventes déclarés par les dirigeants de The Oncology Institute, Inc..

🏦 Hedge Funds

16 fonds institutionnels déclarent une position sur STLN dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

6 articles récents sur STLN.

• Starling Oncology to Participate in Wells Fargo Healthcare Conference
• The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.